skip
net ir
Japanese

Astellas Pharma Inc.

code | 4503Market | TYO1Category of Business | Pharmaceuticals
Inquiry : 3-11, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo Japan 103-8411
TEL : 03-3244-3000


Corporate Presentation

2019/04/25
FY2018 FINANCIAL RESULTS ENDED MARCH 31, 2019
President and CEO Kenji Yasukawa, Ph.D.
Presentation material(PDF:1812KB)
300k
2019/01/31
Q3/FY2018 FINANCIAL RESULTS ENDED DECEMBER 31,2018
Chief Financial Officer Chikachi Takeda
Presentation material¡¡(PDF:1108KB)
300k
2018/12/13
R&D Meeting
President and CEO Kenji Yasukawa, Ph.D
President Astellas Institute for Regenerative Medicine Yoshitsugu Shitaka, Ph.D.
Ophthalmology Therapeutic Area Head, Development Eddy Anglade, MD
Presentation material(PDF:3256KB)
300k
2018/10/31
Q2/FY2018 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2018
President and CEO Kenji Yasukawa, Ph.D
Presentation material(PDF:941KB)
300k
2018/05/22
STRATEGIC PLAN 2018
President and CEO Kenji Yasukawa, Ph.D.
Presentation material(PDF:1434KB)
300k




Precautions in use
Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.

up
Download Plug-in
Get Adobe Reader
Windows Media Player
Real Player
Copyright (c) 2004 Nomura Investor Relations Co., Ltd. All Rights Reserved.
NIR